The Fetal Safety of Hydrocortisone-Pramoxine (Proctofoam-HC) for the Treatment of Hemorrhoids in Late Pregnancy

Neda Ebrahimi; Sabina Vohra; Christelle Gedeon; Hani Akoury; Paul Bernstein; Nicholas Pairaudeau; Johanne Cormier; Lorraine Dontigny; Marc Yvon Arsenault; Claude Fortin; Martine Goyet; Chantal Lafortune; Johanne Lalande; Coralie Beauchamp; Francis Engel; Anne Fortin; Anna Taddio; Tom Einarson; Gideon Koren

doi:10.1016/S1701-2163(16)34802-2

The Fetal Safety of Hydrocortisone-Pramoxine (Proctofoam-HC) for the Treatment of Hemorrhoids in Late Pregnancy

Neda Ebrahimi, Sabina Vohra, Christelle Gedeon, Hani Akoury, Paul Bernstein, Nicholas Pairaudeau, Johanne Cormier, Lorraine Dontigny, Marc Yvon Arsenault, Claude Fortin, Martine Goyet, Chantal Lafortune, Johanne Lalande, Coralie Beauchamp, Francis Engel, Anne Fortin, Anna Taddio, Tom Einarson, Gideon Koren

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Objective: Fetal safety has never been studied for any drug used in the treatment of hemorrhoids. Proctofoam-HC is a combination of a corticosteroid and a local anaesthetic that is proven effective for the treatment of hemorrhoids. The objective of this study was to assess prospectively the fetal safety of third trimester exposure to Proctofoam-HC. Methods: In a multicentre study, 240 women exposed to Proctofoam-HC in the third trimester and a similar number of control pregnant women were followed up postnatally. Results: When compared to controls exposure to Proctofoam-HC was not associated with any adverse fetal effects on birth weight, gestational age, rates of prematurity, or pre- or postnatal complications. Conclusion: Proctofoam-HC is safe to use in the treatment of hemorrhoids in late pregnancy.

Original language	English
Pages (from-to)	153-158
Number of pages	6
Journal	Journal of Obstetrics and Gynaecology Canada
Volume	33
Issue number	2
DOIs	https://doi.org/10.1016/S1701-2163(16)34802-2
State	Published - 2011
Externally published	Yes

Access to Document

10.1016/S1701-2163(16)34802-2

Cite this

Ebrahimi, N., Vohra, S., Gedeon, C., Akoury, H., Bernstein, P., Pairaudeau, N., Cormier, J., Dontigny, L., Arsenault, M. Y., Fortin, C., Goyet, M., Lafortune, C., Lalande, J., Beauchamp, C., Engel, F., Fortin, A., Taddio, A., Einarson, T., & Koren, G. (2011). The Fetal Safety of Hydrocortisone-Pramoxine (Proctofoam-HC) for the Treatment of Hemorrhoids in Late Pregnancy. Journal of Obstetrics and Gynaecology Canada, 33(2), 153-158. https://doi.org/10.1016/S1701-2163(16)34802-2

@article{70d5ffb0d0bf41d2be36c5ce1dfce59c,

title = "The Fetal Safety of Hydrocortisone-Pramoxine (Proctofoam-HC) for the Treatment of Hemorrhoids in Late Pregnancy",

abstract = "Objective: Fetal safety has never been studied for any drug used in the treatment of hemorrhoids. Proctofoam-HC is a combination of a corticosteroid and a local anaesthetic that is proven effective for the treatment of hemorrhoids. The objective of this study was to assess prospectively the fetal safety of third trimester exposure to Proctofoam-HC. Methods: In a multicentre study, 240 women exposed to Proctofoam-HC in the third trimester and a similar number of control pregnant women were followed up postnatally. Results: When compared to controls exposure to Proctofoam-HC was not associated with any adverse fetal effects on birth weight, gestational age, rates of prematurity, or pre- or postnatal complications. Conclusion: Proctofoam-HC is safe to use in the treatment of hemorrhoids in late pregnancy.",

author = "Neda Ebrahimi and Sabina Vohra and Christelle Gedeon and Hani Akoury and Paul Bernstein and Nicholas Pairaudeau and Johanne Cormier and Lorraine Dontigny and Arsenault, {Marc Yvon} and Claude Fortin and Martine Goyet and Chantal Lafortune and Johanne Lalande and Coralie Beauchamp and Francis Engel and Anne Fortin and Anna Taddio and Tom Einarson and Gideon Koren",

note = "Publisher Copyright: {\textcopyright} 2011 Society of Obstetricians and Gynaecologists of Canada.",

year = "2011",

doi = "10.1016/S1701-2163(16)34802-2",

language = "אנגלית",

volume = "33",

pages = "153--158",

journal = "Journal of Obstetrics and Gynaecology Canada",

issn = "1701-2163",

publisher = "Elsevier Inc.",

number = "2",

}

Ebrahimi, N, Vohra, S, Gedeon, C, Akoury, H, Bernstein, P, Pairaudeau, N, Cormier, J, Dontigny, L, Arsenault, MY, Fortin, C, Goyet, M, Lafortune, C, Lalande, J, Beauchamp, C, Engel, F, Fortin, A, Taddio, A, Einarson, T & Koren, G 2011, 'The Fetal Safety of Hydrocortisone-Pramoxine (Proctofoam-HC) for the Treatment of Hemorrhoids in Late Pregnancy', Journal of Obstetrics and Gynaecology Canada, vol. 33, no. 2, pp. 153-158. https://doi.org/10.1016/S1701-2163(16)34802-2

TY - JOUR

T1 - The Fetal Safety of Hydrocortisone-Pramoxine (Proctofoam-HC) for the Treatment of Hemorrhoids in Late Pregnancy

AU - Ebrahimi, Neda

AU - Vohra, Sabina

AU - Gedeon, Christelle

AU - Akoury, Hani

AU - Bernstein, Paul

AU - Pairaudeau, Nicholas

AU - Cormier, Johanne

AU - Dontigny, Lorraine

AU - Arsenault, Marc Yvon

AU - Fortin, Claude

AU - Goyet, Martine

AU - Lafortune, Chantal

AU - Lalande, Johanne

AU - Beauchamp, Coralie

AU - Engel, Francis

AU - Fortin, Anne

AU - Taddio, Anna

AU - Einarson, Tom

AU - Koren, Gideon

PY - 2011

Y1 - 2011

N2 - Objective: Fetal safety has never been studied for any drug used in the treatment of hemorrhoids. Proctofoam-HC is a combination of a corticosteroid and a local anaesthetic that is proven effective for the treatment of hemorrhoids. The objective of this study was to assess prospectively the fetal safety of third trimester exposure to Proctofoam-HC. Methods: In a multicentre study, 240 women exposed to Proctofoam-HC in the third trimester and a similar number of control pregnant women were followed up postnatally. Results: When compared to controls exposure to Proctofoam-HC was not associated with any adverse fetal effects on birth weight, gestational age, rates of prematurity, or pre- or postnatal complications. Conclusion: Proctofoam-HC is safe to use in the treatment of hemorrhoids in late pregnancy.

AB - Objective: Fetal safety has never been studied for any drug used in the treatment of hemorrhoids. Proctofoam-HC is a combination of a corticosteroid and a local anaesthetic that is proven effective for the treatment of hemorrhoids. The objective of this study was to assess prospectively the fetal safety of third trimester exposure to Proctofoam-HC. Methods: In a multicentre study, 240 women exposed to Proctofoam-HC in the third trimester and a similar number of control pregnant women were followed up postnatally. Results: When compared to controls exposure to Proctofoam-HC was not associated with any adverse fetal effects on birth weight, gestational age, rates of prematurity, or pre- or postnatal complications. Conclusion: Proctofoam-HC is safe to use in the treatment of hemorrhoids in late pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=79960091586&partnerID=8YFLogxK

U2 - 10.1016/S1701-2163(16)34802-2

DO - 10.1016/S1701-2163(16)34802-2

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 21352635

AN - SCOPUS:79960091586

SN - 1701-2163

VL - 33

SP - 153

EP - 158

JO - Journal of Obstetrics and Gynaecology Canada

JF - Journal of Obstetrics and Gynaecology Canada

IS - 2

ER -

The Fetal Safety of Hydrocortisone-Pramoxine (Proctofoam-HC) for the Treatment of Hemorrhoids in Late Pregnancy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this